Medicine guide
Aumseqa
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Aumolertinib
- Made by
- SFL Pharmaceuticals Deutschland GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Aumseqa as monotherapy is indicated for:- the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC)whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations (forbiomarker-based patient selection, see section 4.2).- the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC (forbiomarker-based patient selection, see section 4.2)
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | SFL Pharmaceuticals Deutschland GmbH |
|---|---|
| Active substance | Aumolertinib |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L01EB · Cancer treatments and immune-system medicines |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2026-02-12 |
| Last updated by the regulator | 2026-02-27 |
| EMA product number | EMEA/H/C/006069 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).